Latest Articles

Publication Date
New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial - geneonline.com

New Combination Therapy Shows Promise for pMMR Advanced Endometrial Cancer in Phase Ib/II Trial geneonline.com

Published: Dec. 21, 2025, 12:34 p.m.
Adenosarcoma of the uterine cervix – a novel case report and review of the literature - Termedia

Adenosarcoma of the uterine cervix – a novel case report and review of the literature Termedia

Published: Dec. 21, 2025, 8:41 a.m.
Why OrthoPediatrics Corp. stock appeals to dividend seekers - Market Risk Analysis & AI Based Buy and Sell Signals - Улправда

Why OrthoPediatrics Corp. stock appeals to dividend seekers - Market Risk Analysis & AI Based Buy and Sell Signals Улправда

Published: Dec. 20, 2025, 10:57 a.m.
Why OrthoPediatrics Corp. stock appeals to dividend seekers - Market Risk Analysis & AI Based Buy and Sell Signals - ulpravda.ru

Why OrthoPediatrics Corp. stock appeals to dividend seekers - Market Risk Analysis & AI Based Buy and Sell Signals ulpravda.ru

Published: Dec. 20, 2025, 10:57 a.m.
Dysmenorrhoea presentation in Herlyn-Werner-Wunderlich syndrome: A case study.

Herlyn-Werner-Wunderlich syndrome is a rare congenital anomaly characterized by uterus didelphys, obstructed hemi-vagina, and ipsilateral renal agenesis. This study aims to present a case of Herlyn-Werner-Wunderlich syndrome seen at Shifa …

Published: Dec. 20, 2025, midnight
Pharmacokinetic-Pharmacodynamic Modeling and Simulation of Merigolix, a Nonpeptide Gonadotropin-Releasing Hormone Antagonist.

Gonadotropin-releasing hormone (GnRH) antagonists inhibit estrogen synthesis and secretion, making them promising treatment options for estrogen-dependent diseases, such as endometriosis. This study developed a population pharmacokinetic/pharmacodynamic (PK/PD) model for merigolix, …

Published: Dec. 20, 2025, midnight
Copper Intrauterine Device Migration Into Cesarean Scar Niches Without Complications: A Case Report.

Intrauterine devices (IUDs), both hormonal and nonhormonal, are widely used contraceptive methods, with approximately 20% of reproductive-aged women worldwide utilizing them. Although IUDs are generally considered safe and effective, complications …

Published: Dec. 20, 2025, midnight
Non-Invasive Diagnosis of Endometriosis by Questionnaires in Patients Using Contraception.

Background/Objectives: The assessment of endometriosis (EMS)-associated pain is important, but only very few studies address the potential use of questionnaires for non-invasive prediction of the disease. Methods: In a prospective …

Published: Dec. 20, 2025, midnight
Prediction of MBS Item Codes for Endometriosis Surgery Using Transvaginal Ultrasound.

In March 2022, updates in the Australian Medicare Benefits Schedule relating to endometriosis surgery were made relating to item numbers 35637, 35631 and 35632 (division of 35638) and 35641. Updated …

Published: Dec. 19, 2025, midnight
EGR1 promotes ferroptosis in endometriosis through transcriptional activation of HMOX1.

Endometriosis (EM) affects approximately 10% of women of reproductive age and remains a prevalent estrogen-dependent gynecological disorder with limited therapeutic efficacy and high recurrence rates. Ferroptosis-an iron-dependent, non-apoptotic form of …

Published: Dec. 19, 2025, midnight
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!